Roche will pay Nurix Pharmaceuticals up to $2.3 billion for the rights to bexobrutideg, an experimental BTK degrader drug targeting blood cancers, immune, and neurological diseases [1, 2]. Nurix will receive a $700 million upfront payment as part of the agreement [1, 2].
Under the deal, Roche and Nurix will share the development costs and split any U.S. profits equally. Roche will handle commercialization of the therapy outside the U.S. [1, 2]. Bexobrutideg aims to offer potential advantages over existing BTK inhibitors by overcoming resistance mutations commonly found in patients [1].
The exclusive license and collaboration agreement was announced on June 8, 2026 [2]. The transaction is expected to close during the third quarter of 2026 [1, 2].
Following the announcement, Roche’s shares dropped as much as 1.4% in early trading in Zurich [1].
